

2<sup>nd</sup> International Conference on

# CANCER BIOLOGY, THERAPEUTICS AND DRUG DISCOVERY AND DELIVERY

&

10<sup>th</sup> Annual Congress on

# BIOMARKERS, CLINICAL RESEARCH & THERAPEUTICS

October 03-04, 2018 | Los Angeles, USA



## Michael J Powell

PhD. C.Chem, MRSC, DiaCarta Inc., USA

### Rapid, reliable, high sensitivity nucleic acid detection technologies, products and services for cancer diagnosis and therapy monitoring

There is a demand for advanced technologies for the detection of circulating cell-free nucleic acids that can be implemented effectively and universally in the modern translational biology research laboratories and hospital pathology laboratories and clinical testing facilities worldwide. Especially as this relates to cancer detection, cancer therapy, and immunotherapy. This workshop will highlight the most recent developments in this field and how DiaCarta, Inc.'s proprietary technologies, products, and services can provide such a solution for the global monitoring of human disease diagnosis, progression, and therapy.

#### Biography

Michael J Powell is a highly recognized scientific and business leader with more than 25 year's experience in R&D, technology, and business and corporate development. He has extensive knowledge and experience in the fields of molecular diagnostic assay research and development, qPCR and other nucleic acid amplification technologies, and automated instrumentation platforms. He has published many research papers in leading scientific journals and holds more than 40 patents and patent-pending applications. He received his PhD in medicinal organic chemistry from Loughborough University, Loughborough, UK and also pursued postdoctoral research and a teaching fellowship from the University of Nottingham, Nottingham, UK. He was also a postdoctoral industrial research fellow at the University of Oxford, UK and was instrumental in developing the amperometric glucose sensing technology that was the basis of Medisense, Inc. which was acquired by Abbott Labs for \$950M.

[mpowell@diacarta.com](mailto:mpowell@diacarta.com)

Notes: